Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma

Initial nivolumab-based treatment halts melanoma progression

Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma

New intelligence network that supports efforts to improve quality of care and development of new medicines

Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs

Advanced DNA sequencing test used to match rare cancers

Developments in clinical trials and health information technology that will improve targeted therapies for patients

Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer

Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer